<DOC>
	<DOCNO>NCT00065962</DOCNO>
	<brief_summary>Many drug use treat autism target specific symptom , hyperactivity aggressiveness . Few drug target core autistic symptom impair social interaction communication . This study evaluate two form drug secretin treatment core autistic symptom .</brief_summary>
	<brief_title>Secretin Treatment Autism</brief_title>
	<detailed_description>Autism disorder characterize impairment social interaction , verbal nonverbal communication , preoccupation unusual activity interest , particularly stereotype repetitive movement . This debilitate disorder estimate occur 2 10 every 10,000 birth . A primary focus pyschopharmacological intervention treat specific associate symptom , hyperactivity , aggressiveness , temper tantrum ; pharmacologic treatment direct toward core autistic symptom . Secretin gut hormone binding site brain . Previous research describe three patient autism underwent diagnostic endoscopy gastrointestinal complaint experience dramatic improvement autistic symptom follow administration intravenous secretin give part endoscopy . Though result single , uncontrolled study limit interpretive value , many autistic child expose continue expose potential treatment uncontrolled manner . This double blind , placebo-controlled trial evaluate safety efficacy secretin treatment autism . Participants randomly assign one three treatment group : synthetic porcine secretin ( sPS ) , biologically derive porcine secretin ( bPS ) , placebo . Each participant give initial intravenous dose 0.1 ml assign treatment appropriate dose ( 0.2 ug sPS 1 CU bPS ) . If allergic reaction occur within one minute , participant continue study receive full remain dose one minute . Participants evaluate one week four week infusion social , communication , behavioral functioning measure Autistic Diagnostic Observation Schedule Generic ( blinded raters ) ; Rimland Questionnaires ( parent teacher ) ; Expressive Vocabulary Test ; MacArthur Communication Inventory ( parent teacher ) ; Aberrant Behavior Checklist ( parent teacher ) . Participants also physical exam blood urine test . After completion preliminary data analysis , placebo patient offer open label therapy appropriate .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Secretin</mesh_term>
	<criteria>Inclusion Criteria Autism base DSMIV criterion IQ &gt; 35 Medically fit study judgment study official Exclusion Criteria Prior administration secretin Acute chronic pancreatitis Use anticholinergic within 72 hour study entry anticipate need anticholinergic study Allergies pork product Use investigational drug within 1 month study entry Change medication therapeutic modality use treat neurodevelopmental gastrointestinal symptom underlie autism disorder within 1 month study entry Any medical condition , judgment investigator , would make patient unable safely participate study comply study procedures Any medical diagnosis could account autistic spectrum disorder ( i.e. , Rett syndrome , Fragile X , tuberous sclerosis , disintegrative disorder , epilepsy , Landau Kleffner , mental retardation syndrome , history severe motor delay current sensory motor impairment cerebral palsy ) Hearing visual impairment Use psychotropic medication ( except occasional symptomatic use sleep , etc . ) within 6 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>Pervasive Developmental Disorders</keyword>
	<keyword>Secretin , synthetic porcine</keyword>
	<keyword>Secretin , biological porcine</keyword>
	<keyword>Autism Diagnostic Observation Schedule - Generic ( ADOS-G )</keyword>
	<keyword>Rimland Questionnaire</keyword>
	<keyword>Expressive Vocabulary Test</keyword>
	<keyword>MacArthur Communication Inventory</keyword>
	<keyword>Aberrant Behavior Checklist</keyword>
</DOC>